Expert Discusses Key Findings of Longer Term Follow Up of iFCR Therapy Study for Chronic Lymphocytic Leukemia

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses the results of a longer-term follow up for iFCR therapy for individuals with chronic lymphocytic leukemia .

In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).

He discussed the results of a longer-term follow up for iFCR therapy for individuals with CLL.